Loading
A phase 1/2 trial of Bevacizumab in advanced solid tumours, run by Bristol-Myers Squibb, active and no longer recruiting.
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06730750 by Bristol-Myers Squibb, with 360 participants enrolled, started 2025-02-12 and due to reach its primary completion in 2026-09-05. Interventions recorded: BMS-986490 and Bevacizumab.
Shares Bristol Myers Squibb, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bristol Myers Squibb, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies and the tag pipeline.
Shares Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies and the tag pipeline.
Shares Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies and the tag pipeline.
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Monoclonal antibodies, Metastatic cancer (cancer that has spread) and the tag pipeline.